Story
Jazz Pharmaceuticals Stock Climbs on FDA Approval for Cancer Therapy Ziihera

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) gained 2.3% in Tuesday trading following the U.S. Food and Drug Administration's (FDA) approval of its new cancer therapy, Ziihera. The drug is now approved for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA).
Details of the Approval
The FDA greenlit two Ziihera-containing regimens for patients, regardless of their PD-L1 status. Ziihera is the first bispecific HER2-targeted antibody to be approved in combination with a PD-1 inhibitor and chemotherapy for this patient population.
This approval addresses a significant need, as approximately 20% of patients with gastroesophageal adenocarcinoma have HER2-positive disease. According to the source, more than 31,000 new cases of stomach cancer are diagnosed annually in the United States.
Clinical Trial Backing
AdThe regulatory decision was based on positive results from the Phase 3 HERIZON-GEA-01 trial. The study demonstrated that Ziihera-based combinations provided a significant clinical benefit compared to the standard of care, trastuzumab plus chemotherapy.
Key findings from the trial include:
- A 35% reduction in the risk of disease progression or death.
- An extension of median progression-free survival to 12.4 months, compared to 8.1 months for the control arm.
- A 28% reduction in the risk of death in the overall HER2-positive population.
- A median overall survival of 26.4 months, versus 19.2 months for the control arm.
Jazz Pharmaceuticals noted that the median overall survival figure is the longest reported in a Phase 3 trial for patients with HER2-positive advanced GEA. The company also reported that while diarrhea was the most common adverse reaction, it was generally manageable and resulted in few treatment discontinuations.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.